What Phlox Therapeutics does

Phlox Therapeutics B.V. is a Dutch private biotechnology company founded in March 2022 as a spin-off of Amsterdam University Medical Center, headquartered in Naarden, the Netherlands. The company develops RNA-based gene therapies targeting genetic cardiomyopathies, with a primary focus on laminopathies caused by LMNA gene mutations. Its pipeline comprises PHL002, a lead gene therapy designed to restore functional Lamin A/C protein in patients with LMNA-related dilated cardiomyopathy due to haploinsufficiency; PHL001, an RNA therapeutic using smart RNA designs to enable parallel targeting of multiple Lamin A/C mutations; and PHL003, an undisclosed follow-on program. The platform's distinguishing technical element is the ability to address multiple LMNA mutations with a single RNA-based compound, reducing the need for mutation-specific therapeutics.

The company's scientific foundation rests on more than 15 years of academic research from co-founders Prof. Eva van Rooij (CSO, Hubrecht Institute/UMC Utrecht) and Prof. Yigal Pinto (CMO, Amsterdam UMC), supported by public-private partnerships with the Hubrecht Institute and grants from the Dutch Research Council (NWO) and Health~Holland. Strategic capabilities in vector biology and manufacturing are accessed via a research collaboration with Solid Biosciences. Cumulative disclosed capital includes a 2022 FIRST Fund seed, a May 2023 follow-on seed, and a €1.9M round in November 2024 from ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures, and UHSF.

Phlox is pre-revenue and preclinical. Its expected future revenue model is one-time licensing of RNA-based therapeutics and/or product sales upon regulatory approval, with eventual distribution through specialty pharmacy and hospital-based channels for rare disease gene therapy. Customers are currently non-commercial: research collaborators (Solid Biosciences, Amsterdam UMC, Hubrecht Institute, UMC Utrecht) and capital providers (Dutch regional and academic funds, NWO, Health~Holland). The end users the therapy targets are patients with rare genetic cardiomyopathies and the specialist cardiologists treating them.

Name

Phlox Therapeutics

Legal name

Phlox Therapeutics B.V.

Website

https://phloxtherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Phlox Therapeutics is a preclinical Dutch biotech developing RNA-based gene therapies that target multiple LMNA mutations to treat rare genetic cardiomyopathies, with lead program PHL002 advancing toward IND. The company serves patients with laminopathies and LMNA-related dilated cardiomyopathy through future specialty-pharma and hospital-based channels.

Ownership category

akta.pro rank

Product category

Rare disease gene therapy for cardiomyopathies

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

akta.pro secondary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• RNA-based gene therapy
• Cardiac laminopathy treatments
• Genetic cardiomyopathy therapies
• Precision genetic medicines
• RNA therapeutics platform

Headquarters

HQ city

Naarden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. RNA-based therapeutics development and licensing: Pre-revenue biotech company developing first-in-class RNA therapies for genetic cardiomyopathies. Revenue model will likely involve product sales and/or licensing of technology upon successful clinical development and regulatory approval. The company is in preclinical development stage with lead program PHL002 advancing toward IND.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Phlox Therapeutics is a preclinical-stage biotechnology company developing a pipeline of first-in-class RNA-based gene therapies for rare genetic cardiomyopathies, with a primary focus on laminopathies caused by LMNA gene mutations. The platform uses smart RNA designs that simultaneously target multiple Lamin A/C mutations, eliminating the need for mutation-specific compounds. Lead program PHL002 is designed to restore functional Lamin protein in patients with LMNA-related dilated cardiomyopathy, supported by PHL001 (multi-mutation RNA therapeutic) and PHL003 (undisclosed follow-on).

Product overview

Phlox Therapeutics is developing a pipeline of RNA-based gene therapies targeting genetic cardiomyopathies, with a focus on cardiac laminopathies caused by LMNA gene mutations. The company's portfolio consists of three programs: PHL002 (lead candidate), a gene therapy for LMNA-related dilated cardiomyopathy addressing haploinsufficiency; PHL001, an RNA-based therapeutic enabling parallel targeting of multiple Lamin mutations through versatile RNA designs; and PHL003, an undisclosed follow-on program. The platform technology allows simultaneous targeting of multiple lamin mutations, eliminating the need for mutation-specific compounds and making treatments suitable for most lamin mutations.

Differentiator

Problem solved

Functional benefit

Products and services

• PHL002 Lead gene therapy candidate designed to restore functional Lamin protein in patients with LMNA-related dilated cardiomyopathy caused by haploinsufficiency. Targets the underlying genetic defect to slow disease progression and improve cardiac function. Preclinical studies have demonstrated improved survival and disease outcomes in human stem cell-derived cardiomyocytes and human-relevant laminopathy mouse models.
• PHL001 RNA-based therapeutic that enables parallel targeting of multiple Lamin mutations through smart RNA designs. Eliminates the need for mutation-specific compounds, making the therapeutic efficacious for the majority of patients harboring Lamin A/C mutations causing abnormal protein. Proof-of-concept shows selective therapeutic effects in human stem cell-derived cardiomyocytes from patients suffering from laminopathy.
• PHL003 Undisclosed follow-on pipeline program in the Phlox pipeline, targeting genetic cardiomyopathies using the company's RNA-based multi-mutation platform technology.

Quantifiable outcome

• Preclinical studies showed improved survival and disease outcomes in laminopathy models
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Hubrecht InstitutecoreStrategic or Co-development Partner · 1 November 2024Public-private partnership supporting Phlox's research. Technology and design of PHL002 based on research in lab of CSO Prof. Eva van Rooij at the Hubrecht Institute. Collaboration supported by Health~Holland.
• Solid BiosciencescoreStrategic or Co-development Partner · 1 January 2022Strategic research collaboration focused on developing new therapies for rare cardiac diseases, specifically targeting a severe form of genetic dilated cardiomyopathy. Collaboration integrates Solid Biosciences' vector biology, manufacturing capabilities and drug development experience with Phlox's expertise in genetic cardiomyopathies and RNA therapeutics. Supported by grant from Dutch Top Sector Life Sciences and Health.
• Dutch CardioVascular Alliance (DCVA)minorStrategic or Co-development Partner · 1 March 2021Support from DCVA was instrumental in scientific foundation of company. National consortium coordinating translation of novel RNA biology insights toward clinical therapies for cardiomyopathies.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Lexeo Therapeutics: Clinical-stage gene therapy company developing LX2000 for LMNA-related dilated cardiomyopathy, the exact indication Phlox is targeting. Most directly comparable peer given shared therapeutic target and modality.
• Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies for rare cardiomyopathies using AAV delivery. Highly comparable given shared cardiac gene therapy focus, AAV modality, and rare-disease strategy.
• Rocket Pharmaceuticals: Gene therapy company with cardiac programs including RP-A501 for Danon disease. Comparable as a rare cardiac gene therapy developer with established manufacturing and clinical infrastructure.

Emerging players

• Solid Biosciences: AAV gene therapy company focused on Duchenne muscular dystrophy; current strategic collaborator of Phlox. Comparable for shared AAV vector platform and rare genetic disease development playbook.

Broad incumbents

• Regenxbio: Established AAV gene therapy platform company with cardiac and rare disease programs. Comparable as a broader gene therapy platform enabling therapeutic area partners including cardiac indications.
• BridgeBio Pharma: Genetic disease-focused company with cardiac programs (e.g., acoramidis for ATTR-CM). Comparable for rare genetic cardiology focus, though diversified across multiple modalities.
• Ionis Pharmaceuticals: Leader in RNA-targeted therapeutics with cardiovascular pipeline. Comparable for RNA-based therapeutic modality, though operating at much greater scale across multiple disease areas.
• Alnylam Pharmaceuticals: Pioneer in RNAi therapeutics with growing cardiovascular pipeline (e.g., patisiran, vutrisiran). Comparable for RNA-based therapeutic platform addressing rare diseases including cardiac amyloidosis.
• uniQure: Gene therapy company with validated AAV manufacturing platform and cardiac-relevant programs. Comparable as a more mature AAV gene therapy peer with commercial-stage capabilities.
• Lexeo Therapeutics competitor: Pfizer (LMNA program legacy): Large pharma that has historically invested in LMNA cardiomyopathy programs. Comparable as a potential acquirer or competitor with cardiac gene therapy R&D presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/phloxtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phlox Therapeutics